Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study.

Simon PernotOlivier DubreuilThomas AparicioKarine Le MalicotDavid TougeronCéline LepèreCedric LecailleLysiane MartheyJuliette PalleJean-Baptiste BachetAziz ZaananJulien Taieb

Published in: British journal of cancer (2018)

TEFOX appears to be effective as first-line treatment in advanced gastric SRCC and has an acceptable safety profile. It allowed a curative intent approach in 40% of patients. Considering the low chemosensitivity of SRCC reported with other chemotherapy regimens and pending for randomised studies, TEFOX might be an option in advanced gastric SRCC.

Keyphrases

end stage renal disease
prognostic factors
clinical trial
ejection fraction
newly diagnosed
chronic kidney disease
locally advanced
peritoneal dialysis
open label
squamous cell carcinoma
randomized controlled trial
radiation therapy
study protocol
rectal cancer
patient reported outcomes
placebo controlled